Active ingredients: etoposide
What it is used for
This product accepted for registration as 'currently supplied' at the time of commencement of the Act. New indications were approved as specified in the letter of 1 May 1992 from Dr A. Proudfoot. Indicated for use in the treatment of: Acute monocytic and myelomonocytic leukaemia. Small cell carcinoma of the lung. Hodgkin's disease. Non-Hodgkin's lymphoma.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Intravenous
- Store below 25 degrees Celsius
- Protect from Light
- Lifetime is 2 Years.
Always read the label. If symptoms persist see your healthcare professional.
A clear, pale to light yellow, slightly viscous liquid.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.
Is this medicine subsidised?
This medicine may be subsidised which may make it cheaper. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient etoposide
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)